IPO - Outset Medical, Inc.

Form Type: S-3/A

Filing Date: 2025-02-26

Corporate Action: Ipo

Type: New

Accession Number: 000119312525036795

Filing Summary: On February 26, 2025, Outset Medical, Inc. filed an amendment to its registration statement on Form S-3 with the SEC. This filing introduces a base prospectus covering the offering, issuance, and sale of various securities including common stock, preferred stock, warrants, and debt securities. The total offering price is set at $100 million. The registration statement supports both direct offerings and sales by selling stockholders, potentially involving the resale of up to 215,835,000 shares of common stock. The aggregate market value of Outset Medical's common stock held by non-affiliates as of February 12, 2025, was calculated to be $74 million, with the last reported share price at $0.78. This prospectus becomes effective upon filing, and specific offerings will be detailed in subsequent prospectus supplements. Key risk factors and information regarding the planned use of proceeds are also addressed within the document.

Document Link: View Document

Form Type: S-3

Filing Date: 2025-02-13

Corporate Action: Ipo

Type: New

Accession Number: 000119312525026056

Filing Summary: Outset Medical, Inc. filed a Form S-3 Registration Statement with the SEC on February 13, 2025. This registration statement allows the company to offer and sell securities, including common stock, preferred stock, warrants, debt securities, rights to purchase securities, and units, with an aggregate initial offering price of up to $100 million. The document specifies that the company may sell these offerings from time to time after the registration statement becomes effective, with the potential for multiple secondary offerings by selling stockholders covering up to 215,835,000 shares of common stock. The company identifies itself as a smaller reporting company and an accelerated filer, providing reduced disclosure obligations. Outset Medical is known for its Tablo® Hemodialysis System, innovating in the field of dialysis technology. The stock is traded on Nasdaq under the symbol 'OM', with the last reported sale price at $0.78 as of February 12, 2025. The filing also discusses risk factors for potential investors, including the volatility of stock prices and operational risks.

Document Link: View Document